CoDiagnostics (CODX)
(Delayed Data from NSDQ)
$1.17 USD
0.00 (0.00%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $1.18 +0.01 (0.85%) 5:38 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Brokerage Reports
Co-Diagnostics, Inc. [CODX]
Reports for Purchase
Showing records 1 - 20 ( 81 total )
Company: Co-Diagnostics, Inc.
Industry: Medical Services
2Q24 Financial Results Reported; Reiterate Neutral; Modulating PT to $1.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
Co-Dx PCR Pro Instrument and Assay Submitted for 510(k) Clearance; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Co-Diagnostics, Inc.
Industry: Medical Services
1Q24 Financial Results Reported; Reiterate Neutral; Modulating PT to $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
2023 Financial Results Reported; Modulating PT to $2.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
EUA Application For PCR Instrument and COVID-19 Test Submitted; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
3Q23 Financial Results Reported; Reiterate Neutral: Raising PT to $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
2Q23 Financial Results Reported; Reiterate Neutral; Lowering PT to $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
We are dropping coverage of Co-Diagnostics, Inc. due to the reallocation of analysts coverage.
Provider: Litchfield Hills Research, LLC
Analyst: Research Department
Company: Co-Diagnostics, Inc.
Industry: Medical Services
Mixed 1Q23, but expectations low - Reiterate Buy rating and $7 PT
Provider: Litchfield Hills Research, LLC
Analyst: O'NEILL T
Company: Co-Diagnostics, Inc.
Industry: Medical Services
1Q23 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
Building for a Point-Of-Care future post 4Q22 results - Reiterate Buy rating and lowering target to $7 from $25
Provider: Litchfield Hills Research, LLC
Analyst: O'NEILL T
Company: Co-Diagnostics, Inc.
Industry: Medical Services
Full-Year 2022 Financial Results Reported; Downgrade to Neutral with $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
Clinical Trial of Point-of-Care PCR Platform Begins; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
Looking into the POC future post 3Q22 results - Reiterate Buy rating and $25 PT
Provider: Litchfield Hills Research, LLC
Analyst: O'NEILL T
Company: Co-Diagnostics, Inc.
Industry: Medical Services
3Q22 Financial Results Reported; Reiterate Buy; Lowering PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
2Q22 Financial Results Reported; Reiterate Buy; Lowering PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
Lowering estimates and price target post 2Q22 results - Reiterate Buy rating and $25 PT, down from $29
Provider: Litchfield Hills Research, LLC
Analyst: O'NEILL T
Company: Co-Diagnostics, Inc.
Industry: Medical Services
Monkeypox Virus Test Reagents Shipped; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
Principal Design of Monkeypox Test Completed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
1Q22 Consensus but drops forward guidance - Reiterate Buy rating and $29 PT
Provider: Litchfield Hills Research, LLC
Analyst: O'NEILL T